Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Ills Lead To Fears Among Other Indian Drug Makers

This article was originally published in PharmAsia News

Executive Summary

The allegations Ranbaxy Laboratories exported contaminated pharmaceuticals to the United States has brought increased scrutiny of all Indian drug makers by the U.S. FDA. Several of the dozen or more companies that supply drug ingredients to U.S. and European drug makers are concerned the suspicions will bring greater oversight by the drug makers themselves, delaying approvals and shipment clearances. The firms also are concerned about increased costs and added regulatory hurdles hampering their work. The CEO of Neuland said recent communications indicate the U.S. FDA and other U.S. agencies plan more stringent actions to ensure quality compliance and greater disclosure. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts